SEARCH

SEARCH BY CITATION

References

  • 1
    Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-562.
  • 2
    Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513-521.
  • 3
    Bialek SR, Terrault NA. The changing epidemiology and natural history of hepatitis C virus infection. Clin Liver Dis 2006; 10: 697-715.
  • 4
    Leigh JP, Bowlus CL, Leistikow BN. Costs of hepatitis C. Arch Intern Med 2001; 161: 2231-2237.
  • 5
    Davis KL, Mitra D, Medjedovic J, Beam C, Rustgi V. Direct economic burden of chronic hepatitis C virus in a United States managed care population. J Clin Gastroenterol 2011; 45: e17-24.
  • 6
    Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines. MMWR 2010;59(12):85–86.
  • 7
    Chung RT, Anderson J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351: 451-459.
  • 8
    Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-1850.
  • 9
    Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705-716.
  • 10
    Centers for Disease Control and Prevention. A comprehensive strategy for the prevention and control of hepatitis C virus infection and its consequences. Summer 2001. Available at: /www.cdc.gov/hepatitis/HCV/Strategy/PDFs/NatHepCPrevStrategy.pdf. Accessed on June 3, 2011.
  • 11
    Colvin HM, Mitchell AE. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. The Institute of Medicine's Committee on the Prevention and Control of Viral Hepatitis Infections. Washington, DC: National Academies Press; 2010.
  • 12
    McHutchison JG, Bacon BR. Chronic hepatitis C: an age wave of disease burden. Am J Manag Care 2005; 11: S286-S295; quiz, S307-S311.
  • 13
    Pyenson BS, Fitch K, Iwasaki K. Consequences of hepatitis C virus (HCV): costs of a baby boomer epidemic of liver disease. Milliman Report. New York: Pyenson B. Milliman; 2009.
  • 14
    Volk ML, Tocco R, Saini S, Lok AS. Public health impact of antiviral therapy for hepatitis C in the United States. HEPATOLOGY 2009; 50: 1750-1755.
  • 15
    Shehab TM, Orrego M, Chunduri R, Lok AS. Identification and management of hepatitis C patients in primary care clinics. Am J Gastroenterol 2003; 98: 639-644.
    Direct Link:
  • 16
    Kim WR. The burden of hepatitis C in the United States. HEPATOLOGY 2002; 36: S30-S34.
  • 17
    Shehab TM, Sonnad SS, Lok AS. Management of hepatitis C patients by primary care physicians in the USA: results of a national survey. J Viral Hepat 2001; 8: 377-383.
  • 18
    Sroczynski G, Esteban E, Conrads-Frank A, Schwarzer R, Mühlberger N, Wright D, et al. Long-term effectiveness and cost effectiveness of screening for hepatitis C virus infection. Eur J Public Health 2009; 19: 245-253.
  • 19
    Singer ME, Younossi ZM. Cost-effectiveness of screening for hepatitis C virus in asymptomatic, average risk adults: has the time come? Am J Med 2001; 111: 614-621.
  • 20
    Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-714.
  • 21
    Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. HEPATOLOGY 1996; 24: 289-293.
  • 22
    Arias E. United States life tables, 2004. Natl Vital Stat Rep 2007; 56: 1-39.
  • 23
    Hanmer J, Lawrence W, Anderson J, Kaplan R, Fryback D. Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Making 2006; 26: 391-400.
  • 24
    United States Bureau of Labor Statistics. Consumer price index: all urban consumers (current series): medical care component, first half 2010. Available at: www.bls.gov/cpi/. Accessed on Jan 10, 2011.
  • 25
    Shatin D, Schech SD, Patel K, McHutchison JG. Population-based hepatitis C surveillance and treatment in a national managed care organization. Am J Manag Care 2004; 10: 250-256.
  • 26
    Blatt LM, Mutchnick MG, Tong MJ, Klion FM, Lebovics E, Freilich B, et al. Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. J Viral Hepat 2000; 7: 196-202.
  • 27
    Nainan OV, Alter MJ, Kruszon-Moran D, Gao FX, Xia G, McQuillan G, et al. Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. Gastroenterology 2006; 131: 478-484.
  • 28
    Stepanova M, Kanwal F, El-Serag H, Younossi ZM. Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States. HEPATOLOGY 2011; 53: 737-745.
  • 29
    Boccato S, Pistis R, Noventa F, Guido M, Benvegnù L, Alberti A. Fibrosis progression in initially mild chronic hepatitis C. J Viral Hepat 2006; 13: 297-302.
  • 30
    Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
  • 31
    Bruno S, Shiffman ML, Roberts SK, Gane EJ, Messinger D, Hadziyannis SJ, et al. Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. HEPATOLOGY 2010; 51: 388-397.
  • 32
    Centers for Medicare & Medicaid Expenses. 2010 Clinical Diagnostic Laboratory Fee, April 2010 Release Fee Schedule, using the Healthcare Common Procedure Coding System (HCPCS). Available at: https://www.cms.gov/ClinicalLabFeeSched/02_clinlab.asp. Accessed on June 22, 2010.
  • 33
    MAG Mutual Healthcare Solutions. 2010 Physician's Fee and Coding Guide, 21st ed. Atlanta, GA: MAG Mutual Healthcare Solutions, Inc.; 2009.
  • 34
    Younossi ZM, Singer ME, McHutchison JG, Shermock KM. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. HEPATOLOGY 1999; 30: 1318-1324.
  • 35
    Genentech (a member of the Roche group). Pegasys prescribing information. South San Francisco, CA: Genentech, Inc. Available at: http://www.gene.com/gene/products/information/pegasys/. Accessed on June 10, 2010.
  • 36
    First Bank Database. Available at: http://www.firstdatabank.com/. Accessed on June 10, 2010.
  • 37
    Vertex Pharmaceuticals Incorporated. INCIVEK (telaprevir): package pricing is based on May 2011 WAC for NDC 51167-0100-01 (published by Red Book). Montvale, NJ: Thomson Reuters; 2011.
  • 38
    McAdam Marx C, McGarry LJ, Hane CA, Biskupiak J, Deniz B, Brixner DI. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm 2011; 17: 531-546.
  • 39
    Kim WR, Poterucha JJ, Hermans JE, Therneau TM, Dickson ER, Evans RW, et al. Cost-effectiveness of 6 and 48 weeks of interferon-alpha therapy for chronic hepatitis C. Ann Intern Med 1997; 127: 866-874.
  • 40
    Younossi Z, McCormick M, Boparai N, Price LL, Guyatt G. Assessment of utilities and health-related quality of life in patients with chronic liver disease. Am J Gastroenterol 2001; 96: 579-583.
    Direct Link:
  • 41
    Rodger AJ, Jolley D, Thompson SC, Lanigan A, Crofts N. The impact of diagnosis of hepatitis C virus on quality of life. HEPATOLOGY 1999; 30: 1299-1301.
  • 42
    Sanders GD, Bayoumi AM, Holodniy M, Owens DK. Cost-effectiveness of HIV screening in patients older than 55 years of age. Ann Intern Med 2008; 148: 889-903.
  • 43
    Paltiel AD, Walensky RP, Schackman BR, Seage GR, 3rd Mercincavage LM, Weinstein MC, et al. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med 2006; 145: 797-806.
  • 44
    Shiffman ML. Treatment of hepatitis C in 2011: what can we expect? Curr Gastroenterol Rep 2010; 12: 70-75.
  • 45
    Newborn screening expands: recommendations for pediatricians and medical homes-implications for the system. American Academy of Pediatrics Newborn Screening Authoring Committee. Pediatrics 2008; 121: 192-217.
  • 46
    Arora S, Thornton K, Murata G, Deming P, Kalishman S, Dion D, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med 2011; 364: 2199-2207.